Correction to: Blood Cancer Journal 10.1038/s41408-023-00966-9, published online 02 February 2024
The graphical abstract was missing from this article and should have appeared as below.
The original article has been corrected.
. 2024 Mar 6;14(1):40. doi: 10.1038/s41408-024-01018-6
Correction: GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Paula Rodriguez-Otero
1,✉, Niels W C J van de Donk
2, Kodandaram Pillarisetti
3, Ingrid Cornax
4, Deeksha Vishwamitra
3, Kathleen Gray
5, Brandi Hilder
3, Jaszianne Tolbert
3, Thomas Renaud
6, Tara Masterson
3, Christoph Heuck
3, Colleen Kane
3, Raluca Verona
3, Philippe Moreau
7, Nizar Bahlis
8, Ajai Chari
9
Paula Rodriguez-Otero
1Clínica Universidad de Navarra, CCUN, University of Navarra, Pamplona, Spain
Find articles by Paula Rodriguez-Otero
Niels W C J van de Donk
2Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
Find articles by Niels W C J van de Donk
Kodandaram Pillarisetti
3Janssen Research & Development, Spring House, PA USA
Find articles by Kodandaram Pillarisetti
Deeksha Vishwamitra
3Janssen Research & Development, Spring House, PA USA
Find articles by Deeksha Vishwamitra
Jaszianne Tolbert
3Janssen Research & Development, Spring House, PA USA
Find articles by Jaszianne Tolbert
Tara Masterson
3Janssen Research & Development, Spring House, PA USA
Find articles by Tara Masterson
Christoph Heuck
3Janssen Research & Development, Spring House, PA USA
Find articles by Christoph Heuck
Nizar Bahlis
8Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta Canada
Find articles by Nizar Bahlis
1Clínica Universidad de Navarra, CCUN, University of Navarra, Pamplona, Spain
2Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
3Janssen Research & Development, Spring House, PA USA
4Janssen Research & Development, La Jolla, CA USA
5Janssen Scientific Affairs, Horsham, PA USA
6Janssen Research & Development, Raritan, NJ USA
7University Hospital Hôtel-Dieu, Nantes, France
8Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta Canada
9Icahn School of Medicine at Mount Sinai, New York, NY USA
✉
Corresponding author.
Collection date 2024 Dec.
Subject terms: Myeloma, Drug development, Immunotherapy
© The Author(s) 2024
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
PMCID: PMC10918080 PMID: 38448422
This corrects the article "GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review", 24.